FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug

Yesterday the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met to discuss DURECT Corporation’s Posimir. The adcom had a 6-to-6 vote on whether to recommend approval of the drug.